Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)
Close on Nov 13, 2026Market cap $153.37MP/E –Yield –
Fate Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Fate Therapeutics's total debt was $13.93M at Sep 30, 2019. For fiscal 2018 it was $14.88M, up 0.5% from the year before. The highest annual figure on record is $19.61M in fiscal 2014.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $14.88M | +0.5% |
| FY2017 | Dec 31, 2017 | $14.81M | +38.5% |
| FY2016 | Dec 31, 2016 | $10.69M | -41.4% |
| FY2015 | Dec 31, 2015 | $18.24M | -7.0% |
| FY2014 | Dec 31, 2014 | $19.61M | +1032.1% |
| FY2013 | Dec 31, 2013 | $1.73M | -52.8% |
| FY2012 | Dec 31, 2012 | $3.67M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2019 | Sep 30, 2019 | $13.93M | -6.3% |
| Q2 FY2019 | Jun 30, 2019 | $14.92M | +0.5% |
| Q1 FY2019 | Mar 31, 2019 | $14.90M | +0.5% |
| Q4 FY2018 | Dec 31, 2018 | $14.88M | +0.5% |
| Q3 FY2018 | Sep 30, 2018 | $14.87M | +0.5% |
| Q2 FY2018 | Jun 30, 2018 | $14.85M | +122.4% |
| Q1 FY2018 | Mar 31, 2018 | $14.83M | +70.4% |
| Q4 FY2017 | Dec 31, 2017 | $14.81M | +38.5% |
| Q3 FY2017 | Sep 30, 2017 | $14.79M | – |
| Q2 FY2017 | Jun 30, 2017 | $6.68M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.69M | – |
See a number that looks wrong?